

**Supplementary information for:**

**Chemogenomic screening identifies the Hsp70 co-chaperone DNAJA1 as a hub for anticancer drug resistance**


Nitika<sup>1</sup>, Jacob S. Blackman<sup>1</sup>, Laura E. Knighton<sup>1</sup>, Jade E. Takakuwa<sup>1</sup>, Stuart K. Calderwood<sup>2</sup> and Andrew W. Truman<sup>1\*</sup>

<sup>1</sup>Department of Biological Sciences, University of North Carolina Charlotte, Charlotte, NC 28223, USA







<sup>2</sup>Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave, Boston, MA 02215, USA

\*Corresponding author

E-mail: [A.Truman@uncc.edu](mailto:A.Truman@uncc.edu)



**Fig. S1. Expression of various chaperone/co-chaperone proteins in HAP1 WT/DNAJA1 knockout cells.** Cell lysates extracted from HAP1 WT and DNAJA1 CRISPR KO cells were resolved on SDS-PAGE gels and further processed by immunoblotting with anti-DNAJA1, Actin, Hsc70, Hsp70, Hsp90, Bag-3, Hsp110 and Actin antibodies.



**Fig. S2. Effects of selected FDA-approved drugs on LnCaP cells.** LNCaP cells were treated with serial dilutions of indicated drugs for 3 days. Cell viability was determined using Cell Titer Glo assay and results shown are average and SD from three replicates (\*\*\*) $P < 0.001$  compared to DMSO control, t-test).